Trials / Completed
CompletedNCT07086079
A Study of Doravirine/Islatravir in Healthy Lactating Females (MK-8591A-061)
A Clinical Study to Evaluate the Breast Milk and Plasma Pharmacokinetics of MK-8591A in Healthy Lactating Female Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The goal of this study is to learn what happens to doravirine (DOR) and islatravir (ISL) in a healthy lactating female's body over time. Researchers want to learn if DOR and ISL are in breast milk.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DOR/ISL | Oral tablet |
Timeline
- Start date
- 2025-09-26
- Primary completion
- 2025-12-08
- Completion
- 2026-02-04
- First posted
- 2025-07-25
- Last updated
- 2026-02-20
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07086079. Inclusion in this directory is not an endorsement.